{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:51:31Z","timestamp":1768459891122,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01365-w","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:23:36Z","timestamp":1768278216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination"],"prefix":"10.1038","volume":"11","author":[{"given":"Annette B.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonny G.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isis","family":"Kanevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie A.","family":"Krumm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alptekin","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan S.","family":"Maddur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin C.","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Witzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Vascotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Stanganello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayuko","family":"Ota-Setlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly J.","family":"Cottingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omaira","family":"Allbritton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Keverne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia","family":"Arag\u00e3o-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem","family":"T\u00fcreci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U\u011fur","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1365_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e286 (2020).","journal-title":"Cell"},{"key":"1365_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","volume":"324","author":"Y He","year":"2004","unstructured":"He, Y. et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324, 773\u2013781 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1365_CR3","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396, 1979\u20131993 (2021).","journal-title":"Lancet"},{"key":"1365_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1365_CR5","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1365_CR6","unstructured":"Paul-Ehrlich-Institut. COVID-19 Vaccines. https:\/\/www.pei.de\/EN\/medicinal-products\/vaccines-human\/covid-19\/covid-19-node.html (2023)."},{"key":"1365_CR7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K R\u00f6ltgen","year":"2022","unstructured":"R\u00f6ltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025\u20131040.e1014 (2022).","journal-title":"Cell"},{"key":"1365_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543\u2013555 (2022).","journal-title":"Nat. Immunol."},{"key":"1365_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00742-7","volume":"8","author":"AJ Krauson","year":"2023","unstructured":"Krauson, A. J., Casimero, F. V. C., Siddiquee, Z. & Stone, J. R. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines 8, 141 (2023).","journal-title":"NPJ Vaccines"},{"key":"1365_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"1365_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.virol.2017.10.013","volume":"514","author":"MJ Hogan","year":"2018","unstructured":"Hogan, M. J. et al. Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime\/protein boost immunization. Virology 514, 106\u2013117 (2018).","journal-title":"Virology"},{"key":"1365_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.immuni.2008.11.007","volume":"30","author":"P Tolar","year":"2009","unstructured":"Tolar, P., Hanna, J., Krueger, P. D. & Pierce, S. K. The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity 30, 44\u201355 (2009).","journal-title":"Immunity"},{"key":"1365_CR13","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.15252\/embj.201694177","volume":"35","author":"C Volkmann","year":"2016","unstructured":"Volkmann, C. et al. Molecular requirements of the B-cell antigen receptor for sensing monovalent antigens. Embo J. 35, 2371\u20132381 (2016).","journal-title":"Embo J."},{"key":"1365_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"1365_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"1365_CR16","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1365_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","volume":"604","author":"W Kim","year":"2022","unstructured":"Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141\u2013145 (2022).","journal-title":"Nature"},{"key":"1365_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","volume":"185","author":"PA Mudd","year":"2022","unstructured":"Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603\u2013613.e615 (2022).","journal-title":"Cell"},{"key":"1365_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572\u2013577 (2021).","journal-title":"Nature"},{"key":"1365_CR20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.016175","volume":"296","author":"B Boson","year":"2021","unstructured":"Boson, B. et al. The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. J. Biol. Chem. 296, 100111 (2021).","journal-title":"J. Biol. Chem."},{"key":"1365_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty, S. T. Follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132\u20131148 (2019).","journal-title":"Immunity"},{"key":"1365_CR22","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.4049\/jimmunol.0803009","volume":"182","author":"D Konforte","year":"2009","unstructured":"Konforte, D., Simard, N. & Paige, C. J. IL-21: an executor of B cell fate. J. Immunol. 182, 1781\u20131787 (2009).","journal-title":"J. Immunol."},{"key":"1365_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","volume":"78","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M., Kleine-Weber, H. & P\u00f6hlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779\u2013784.e775 (2020).","journal-title":"Mol. Cell"},{"key":"1365_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"1365_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"1365_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3389\/fimmu.2018.00598","volume":"9","author":"CM Snapper","year":"2018","unstructured":"Snapper, C. M. Distinct immunologic properties of soluble versus particulate antigens. Front. Immunol. 9, 598 (2018).","journal-title":"Front. Immunol."},{"key":"1365_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni1547","volume":"9","author":"D Depoil","year":"2008","unstructured":"Depoil, D. et al. CD19 is essential for B cell activation by promoting B cell receptor\u2013antigen microcluster formation in response to membrane-bound ligand. Nat. Immunol. 9, 63\u201372 (2008).","journal-title":"Nat. Immunol."},{"key":"1365_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678\u2013680 (2022).","journal-title":"Science"},{"key":"1365_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05377-3","volume":"15","author":"AS Mat Yassim","year":"2025","unstructured":"Mat Yassim, A. S. et al. A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting. Sci. Rep. 15, 21175 (2025).","journal-title":"Sci. Rep."},{"key":"1365_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100529","volume":"3","author":"V-V Edara","year":"2022","unstructured":"Edara, V.-V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep. Med. 3, 100529 (2022).","journal-title":"Cell Rep. Med."},{"key":"1365_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2022","unstructured":"Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N. Engl. J. Med. 386, 492\u2013494 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1365_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/vaccines9050431","volume":"9","author":"D Lain\u0161\u010dek","year":"2021","unstructured":"Lain\u0161\u010dek, D. et al. A nanoscaffolded spike-RBD vaccine provides protection against SARS-CoV-2 with minimal anti-scaffold response. Vaccines 9, 431 (2021).","journal-title":"Vaccines"},{"key":"1365_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf4100","volume":"15","author":"GBE Stewart-Jones","year":"2023","unstructured":"Stewart-Jones, G. B. E. et al. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Sci. Transl. Med. 15, eadf4100 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1365_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106256","volume":"26","author":"I Montgomerie","year":"2023","unstructured":"Montgomerie, I. et al. Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. iScience 26, 106256 (2023).","journal-title":"iScience"},{"key":"1365_CR35","doi-asserted-by":"crossref","unstructured":"Chalkias, S. et al. Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial. Lancet Infect. Dis. 25, p1230\u20131242 (2025).","DOI":"10.1016\/S1473-3099(25)00236-1"},{"key":"1365_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1074-7613(00)00052-2","volume":"13","author":"JE Slansky","year":"2000","unstructured":"Slansky, J. E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13, 529\u2013538 (2000).","journal-title":"Immunity"},{"key":"1365_CR37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jmb.2004.09.079","volume":"344","author":"S Meier","year":"2004","unstructured":"Meier, S., G\u00fcthe, S., Kiefhaber, T. & Grzesiek, S. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. J. Mol. Biol. 344, 1051\u20131069 (2004).","journal-title":"J. Mol. Biol."},{"key":"1365_CR38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG Orlandini von Niessen","year":"2019","unstructured":"Orlandini von Niessen, A. G. et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening. Mol. Ther. 27, 824\u2013836 (2019).","journal-title":"Mol. Ther."},{"key":"1365_CR39","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","volume":"108","author":"S Holtkamp","year":"2006","unstructured":"Holtkamp, S. et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009\u20134017 (2006).","journal-title":"Blood"},{"key":"1365_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-1-62703-260-5_4","volume":"969","author":"E Grudzien-Nogalska","year":"2013","unstructured":"Grudzien-Nogalska, E. et al. Synthetic mRNAs with superior translation and stability properties. Methods Mol. Biol. 969, 55\u201372 (2013).","journal-title":"Methods Mol. Biol."},{"key":"1365_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00253-006-0675-0","volume":"73","author":"S Berensmeier","year":"2006","unstructured":"Berensmeier, S. Magnetic particles for the separation and purification of nucleic acids. Appl Microbiol. Biotechnol. 73, 495\u2013504 (2006).","journal-title":"Appl Microbiol. Biotechnol."},{"key":"1365_CR42","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"1365_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","volume":"28","author":"JB Case","year":"2020","unstructured":"Case, J. B. et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe 28, 475\u2013485.e475 (2020).","journal-title":"Cell Host Microbe"},{"key":"1365_CR44","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 384, 1466\u20131468 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1365_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19055-7","volume":"11","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 11, 5214 (2020).","journal-title":"Nat. Commun."},{"key":"1365_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17892-0","volume":"11","author":"AE Muruato","year":"2020","unstructured":"Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 11, 4059 (2020).","journal-title":"Nat. Commun."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01365-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01365-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01365-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:02:26Z","timestamp":1768417346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01365-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01365-w","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that U.S. and \u00d6.T. are management board members and employees at BioNTech SE (Mainz, Germany); A.B.V., B.G.L., A.M., S.A.K., A.G., K.C.W., S.W., L.A-S., \u00d6.T., and U.S. are employees at BioNTech SE and may hold securities from BioNTech SE. K.T., I.K., K.J.C., O.A., and K.A.S. are current employees at Pfizer (Pearl River, NY) and may hold securities from Pfizer. M.S.M. and A.O.S. were previously employed by Pfizer. JK was previously employed by BioNTech SE. A.B.V., A.M., A.G., K.C.W., S.W., \u00d6.T., and U.S. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}